Anadolu Medical Center
| Turchia | Austria | Spagna | |
| CyberKnife per il tumore polmonare | da $6,000 | - | da $8,057 |
Il Dr. Solak è specializzato nel trattamento del cancro al polmone con un'ampia esperienza presso istituzioni prestigiose, tra cui l'Università di Hacettepe e il MD Anderson Cancer Center.
Dr. Banu Atalar is a board-certified radiation oncologist (Türkiye, 2004). She is a Full Professor at Acibadem MAA University (2018–present) and a clinician at Anadolu Medical Center (2026–present). She trained at Istanbul and Cerrahpaşa. In 2011, she completed a Stanford clinical research fellowship in stereotactic radiosurgery. Her practice focuses on CNS, thoracic, and GI tumors. About 75% of her care involves SRS and MR‑guided adaptive SRS.
Her honors include the ASCO IDEA award (2004), the IASLC International Mentorship Award (2018), and H.FACR (2025). She has 72 international peer‑reviewed publications. Her leadership roles include President of the Turkish Society for Radiation Oncology (2025–27) and Chair of the ESTRO National Societies Committee (2024–27). She served on the ASCO Resource‑Stratified Guidelines Committee (2013–18) and on RSS meeting and nomination committees. She organized national congresses (2023, 2025) and has been an invited speaker at major meetings.
Dr. Kayihan Engin is a Radiation Oncologist. He earned his medical degree from Uludağ University Medical College in 1983. He completed his residency in Radiation Oncology at the Center of Oncology & Nuclear Medicine in Istanbul in 1990. From 1990 to 1994, he pursued a post-doctoral fellowship in Thermoradiotherapy at Thomas Jefferson University in the USA.
Dr. Engin has held key academic and leadership roles. He served as Professor, Chairman, and Faculty Accreditation Coordinator at Uludağ University Medical College from 1991 to 2005. He was also Professor and Director at Anadolu Medical Center between 2004 and 2017. Since 2017, he has led the Oncological Sciences departments at Ceylan International and Medicana Bursa Hospitals. Dr. Engin is known for his work in improving cancer treatment and medical education standards in Turkey.
CyberKnife is a non-invasive radiation therapy, not a traditional surgery. It uses robotic technology to deliver high-dose radiation with sub-millimeter precision. This stereotactic radiosurgery (SBRT) targets tumors without incisions, anesthesia, or hospital stays, making it a highly effective alternative for lung cancer patients in Turkey.
Bookimed Expert Insight: While CyberKnife avoids the operating room, its success often depends on fiducial markers. Top Istanbul clinics like Anadolu Medical Center or Medipol use real-time tracking to adjust for your breathing. This precision allows some patients to fly home just 1 day after their final session.
Patient Consensus: Patients describe the experience as painless zaps from outside the body. Many are surprised to return to normal activities within days, noting fatigue is more common than actual pain.
CyberKnife treatment for lung cancer in Turkey achieves local tumor control rates between 83% and 94%. For early-stage non-small cell lung cancer, success rates frequently exceed 90%. Patients benefit from advanced M6 series technology and real-time robotic tracking at JCI-accredited centers in Istanbul and Ankara.
Bookimed Expert Insight: Success depends heavily on the multidisciplinary team rather than just the machine. While many clinics offer CyberKnife, only a few like Anadolu Medical Center have OECI (Organisation of European Cancer Institutes) accreditation. This distinction ensures your radiation oncologist works directly with staff pulmonologists and pathologists to manage potential post-treatment pneumonitis effectively.
Patient Consensus: Patients emphasize the importance of verifying tumor eligibility before traveling, as centers may refuse advanced stages. Many report temporary fatigue but value the non-invasive nature of the 3-to-5 session protocol.
Ideal candidates for CyberKnife lung cancer treatment typically include patients with early-stage non-small cell lung cancer (NSCLC) or those with medically inoperable tumors. This non-invasive robotic radiosurgery is specifically effective for Stage I or II peripheral tumors smaller than 5 centimeters that shift during breathing.
Bookimed Expert Insight: CyberKnife costs in Turkey range from $4,800 to $10,300, which is roughly _price_percent_discount_% less than US averages. Top-tier centers like Anadolu Medical Center maintain affiliations with Johns Hopkins, providing access to professors like Dr. Banu Atalar who specializes in thoracic stereotactic radiosurgery.
Patient Consensus: Patients emphasize the importance of confirming the tumor is peripherally located rather than central before traveling. They often highlight the relief of avoiding incisions while managing conditions like chronic respiratory failure during treatment.
CyberKnife for lung cancer typically causes mild, temporary side effects that resolve within weeks. Common symptoms include fatigue and skin irritation at the treatment site. Patients may also experience respiratory-specific effects like a mild cough, chest tightness, or shortness of breath due to localized inflammation.
Bookimed Expert Insight: Data from top Turkish centers like Anadolu Medical Center shows a trend toward using MR-guided adaptive SRS. This technology allows surgeons like Dr. Banu Atalar to adjust the beam in real-time. This precision significantly reduces radiation exposure to healthy lung tissue compared to standard linear accelerators.
Patient Consensus: Patients emphasize that recovery is not linear and fatigue can persist for a month. They recommend monitoring for fever or a worsening cough, as early steroid treatment for pneumonitis is professional advice often shared among survivors.
CyberKnife for lung cancer typically requires 1 to 5 non-invasive sessions to achieve tumor ablation. Most Turkish oncology centers complete treatment within 3 to 4 outpatient visits. These robotic radiosurgery sessions last 30 to 90 minutes each, often scheduled every other day to protect healthy lung tissue.
Bookimed Expert Insight: Turkish oncology leaders like Dr. Banu Atalar at Anadolu Medical Center, who trained under the CyberKnife inventor, prioritize specific spacing. While some clinics suggest consecutive days, data shows every-other-day sessions allow healthy lung cells to recover better between high-dose fractions. Requesting an MR-guided adaptive plan can further refine accuracy if the tumor is located near moving structures like the diaphragm.
Patient Consensus: Patients value how this outpatient approach avoids the 20 to 30 sessions required by traditional radiation. Many report that the flexibility of 1 to 3 day gaps between sessions makes the travel schedule much more manageable.
International patients for CyberKnife lung cancer treatment in Turkey typically experience a streamlined, outpatient process requiring only 1 to 3 days for the procedure. The journey focuses on precision stereotactic radiosurgery within Joint Commission International (JCI) accredited facilities, often involving no overnight hospital stay and minimal recovery time.
Bookimed Expert Insight: While the medical procedure itself is brief, the most successful outcomes are found at clinics affiliated with major international bodies like Johns Hopkins Medicine. These centers often maintain a 4.6 or higher patient rating and provide dedicated international coordinators to bridge communication gaps. Booking a hotel within 15 minutes of the clinic is a frequent strategic choice to manage the short-term fatigue that affects patients for 1 to 3 days post-treatment.
Patient Consensus: Many patients find the logistical ease of e-Visas and inclusive airport transfers reduces stress. While treatment is quick, most suggest budgeting for a week-long stay to allow for rest and local follow-up scans before flying home.